Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report

Autor: Maureen Bernadach, Xavier Durando, Jonathan Wong-Chong, Angeline Ginzac, Hugo Veyssière

Publikováno v: World Journal of Clinical Cases
World Journal of Clinical Cases, 2021, 9 (5), pp.1139-1147. ⟨10.12998/wjcc.v9.i5.1139⟩
World Journal of Clinical Cases, Baishideng Publishing Group 2021, 9 (5), pp.1139-1147. ⟨10.12998/wjcc.v9.i5.1139⟩

BACKGROUND Thymic epithelial carcinomas are rare and have a poor prognosis. Treatment of thymic epithelial carcinoma is multimodal and includes surgery, post-operative radiation therapy, adjuvant and neoadjuvant chemotherapy, or exclusive chemotherap

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73bc09e8771b4ebaaa0eb92817f36adc
https://hal.archives-ouvertes.fr/hal-03211502